Alligator Bioscience AB (publ) (ATORX.ST)
SEK 5.21
(94627.27%)
SEK 5.21
(94627.27%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -237.61 Million SEK | -33.86% |
| 2022 | -180.99 Million SEK | -38.84% |
| 2021 | -130.36 Million SEK | 0.84% |
| 2020 | -131.46 Million SEK | 33.65% |
| 2019 | -197.73 Million SEK | -37.48% |
| 2018 | -144.14 Million SEK | -138.1% |
| 2017 | -60.55 Million SEK | -3787.93% |
| 2016 | -45.8 Million SEK | -100.71% |
| 2015 | 220.04 Million SEK | 398.99% |
| 2014 | -73.96 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -45.41 Million SEK | 21.07% |
| 2024 Q3 | -59.71 Million SEK | -33.66% |
| 2024 Q1 | -57.62 Million SEK | 14.72% |
| 2023 Q3 | -49.66 Million SEK | 18.39% |
| 2023 Q2 | -60.86 Million SEK | -1.91% |
| 2023 FY | - SEK | -33.86% |
| 2023 Q1 | -59.72 Million SEK | -29.72% |
| 2023 Q4 | -68.88 Million SEK | -38.69% |
| 2022 Q1 | -40.22 Million SEK | -17.54% |
| 2022 FY | - SEK | -38.84% |
| 2022 Q4 | -46.03 Million SEK | 8.18% |
| 2022 Q3 | -50.13 Million SEK | -12.55% |
| 2022 Q2 | -44.54 Million SEK | -10.75% |
| 2021 FY | - SEK | 0.84% |
| 2021 Q2 | -31.21 Million SEK | -3.39% |
| 2021 Q3 | -34.78 Million SEK | -11.42% |
| 2021 Q4 | -34.21 Million SEK | 1.62% |
| 2021 Q1 | -30.19 Million SEK | 6.01% |
| 2020 Q2 | -31.81 Million SEK | 20.08% |
| 2020 Q3 | -27.72 Million SEK | 12.83% |
| 2020 FY | - SEK | 33.65% |
| 2020 Q4 | -32.12 Million SEK | -15.84% |
| 2020 Q1 | -39.8 Million SEK | 29.96% |
| 2019 Q2 | -46.3 Million SEK | -11.91% |
| 2019 FY | - SEK | -37.48% |
| 2019 Q4 | -56.83 Million SEK | -5.98% |
| 2019 Q3 | -53.62 Million SEK | -15.81% |
| 2019 Q1 | -41.37 Million SEK | -21.81% |
| 2018 Q3 | -36.8 Million SEK | -3.74% |
| 2018 Q4 | -33.97 Million SEK | 7.7% |
| 2018 Q1 | -37.89 Million SEK | -595.19% |
| 2018 FY | - SEK | -138.1% |
| 2018 Q2 | -35.47 Million SEK | 6.38% |
| 2017 Q3 | -23.09 Million SEK | 17.62% |
| 2017 FY | - SEK | -3787.93% |
| 2017 Q1 | -17.05 Million SEK | 12.92% |
| 2017 Q2 | -28.03 Million SEK | -64.39% |
| 2017 Q4 | 7.65 Million SEK | 133.13% |
| 2016 Q2 | 838 Thousand SEK | -96.64% |
| 2016 Q1 | 24.95 Million SEK | 187.31% |
| 2016 FY | - SEK | -100.71% |
| 2016 Q4 | -19.58 Million SEK | -199.83% |
| 2016 Q3 | -6.53 Million SEK | -879.47% |
| 2015 FY | - SEK | 398.99% |
| 2015 Q3 | 279.17 Million SEK | 0.0% |
| 2015 Q4 | -28.58 Million SEK | -110.24% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -962.532% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 25.153% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 15.75% |
| Xintela AB (publ) | -53.47 Million SEK | -344.379% |
| Active Biotech AB (publ) | -43.88 Million SEK | -441.422% |
| Amniotics AB (publ) | -27.14 Million SEK | -775.415% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -1571.337% |
| BioArctic AB (publ) | 275.38 Million SEK | 186.284% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 35.396% |
| Camurus AB (publ) | 562.54 Million SEK | 142.239% |
| Cantargia AB (publ) | -284.31 Million SEK | 16.426% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1113.617% |
| CombiGene AB (publ) | -35.33 Million SEK | -572.441% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -68.699% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -1290.815% |
| Genovis AB (publ.) | 64.57 Million SEK | 467.983% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -106.788% |
| Mendus AB (publ) | -97.84 Million SEK | -142.845% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -541.784% |
| Intervacc AB (publ) | -68.98 Million SEK | -244.468% |
| Kancera AB (publ) | -61.88 Million SEK | -283.936% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -787.182% |
| LIDDS AB (publ) | -39.67 Million SEK | -498.977% |
| Lipum AB (publ) | -37.11 Million SEK | -540.141% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -1863.103% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 856.636% |
| NextCell Pharma AB | -40.98 Million SEK | -479.756% |
| OncoZenge AB (publ) | 7.26 Million SEK | 3370.217% |
| Saniona AB (publ) | -69.69 Million SEK | -240.934% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -39.925% |
| Ziccum AB (publ) | -20.34 Million SEK | -1068.096% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 11880800.0% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -11323.75% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -1669.146% |
| Corline Biomedical AB | -1.69 Million SEK | -13951.685% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -37.092% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -333.555% |
| Aptahem AB (publ) | -10 Million SEK | -2273.95% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 2157.442% |
| Fluicell AB (publ) | -25.91 Million SEK | -816.933% |
| Biovica International AB (publ) | -119.5 Million SEK | -98.83% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -462.746% |
| AcouSort AB (publ) | -16.7 Million SEK | -1322.583% |
| Abliva AB (publ) | -93.6 Million SEK | -153.839% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 25.536% |
| 2cureX AB (publ) | -35.13 Million SEK | -576.269% |
| I-Tech AB | 30.34 Million SEK | 883.042% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 66.747% |
| Cyxone AB (publ) | -20.41 Million SEK | -1063.976% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -131.925% |
| Biosergen AB | 228 Thousand SEK | 104316.667% |
| Nanologica AB (publ) | -62.11 Million SEK | -282.514% |
| SynAct Pharma AB | -222.7 Million SEK | -6.696% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -441.743% |
| BioInvent International AB (publ) | -312.7 Million SEK | 24.014% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 76895.093% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 565861.09% |
| Oncopeptides AB (publ) | -231.62 Million SEK | -2.587% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -2596.336% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -118.882% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -1971.794% |